Company Offers $1 Competitor to Turing's Daraprim

Source: San Diego Tribune

Oct 23, 2015

San Diego biotech Imprimis Pharmaceuticals has introduced a competitor to Turing Pharmaceuticals' $750 a capsule Daraprim.

Imprimis' $1 version is a combination of pyrimethamine along with another generic, leucovorin, a form of folic acid.

Imprimis' substitute drug is a customized formulation that can be used to treat toxoplasmosis. The formulation is not FDA-approved, thus can legally only be sold through a doctor's prescription to a specific individual. The specific ingredients are FDA-approved and the compounding operations are FDA-inspected.

Read the Tribune article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments